Brazil's latest week combined a new Phase I registry signal, ANVISA action across multiple development programs, advanced-therapy amendments, and a clinical-operations capacity indicator.
Brazil clinical trials · ANVISA · ReBEC · Phase I · protocol amendments · advanced therapies · clinical operations · clinical trial AI
Brazil's latest clinical-research week combined three different signals: a new Phase I registry entry, ANVISA action across multiple medicine and biological-product development programs, and visible demand for clinical-monitoring talent. Together, they show a pipeline moving at several levels, from first-stage research through protocol maintenance and operational capacity.
The important distinction is that regulatory movement is not the same as trial activation. A sponsor still has to align the dossier, ethics review, sites, imports, contracts, and operational readiness before first patient in. This edition separates what the sources confirm from what they do not.
ANVISA's Resolução-RE nº 3.162, dated August 12, 2026, records clinical-research actions involving investigational medicines and biological products associated with Eurofarma, AstraZeneca, Novo Nordisk, Merck Sharp & Dohme, Astellas, GSK, AbbVie, IQVIA RDS Brazil, and Eli Lilly (ANVISA RE 3.162, Diário Oficial da União, August 13, 2026).
The resolution covers both clinical-development dossier activity and substantial amendments. Named programs include AstraZeneca's AZD0305 and lenbelintide/AZD6234, Novo Nordisk's zenagamtide, Merck's MK-1045, Astellas's setidegrasib/ASP3082, and GSK's risvutatug rezetecan/GSK5764227. It also records substantial amendment activity involving AbbVie's upadacitinib, IQVIA-managed programs for litifilimab and acasunlimab, and Eli Lilly's tersolisib.
Why It Matters: This is evidence of active regulatory throughput across several development programs, not evidence that each study has opened sites or enrolled participants. The resolution does not provide phases, site locations, enrollment figures, or first-patient dates. Those details should not be inferred from a docket action.
A separate act, Resolução-RE nº 3.143, dated August 10, 2026, records two substantial protocol-amendment decisions tied to REGENXBIO's long-term follow-up studies for RGX-121 and RGX-111. Medpace do Brasil Pesquisa Clínica Ltda. is listed as the applicant (ANVISA RE 3.143, Diário Oficial da União, August 11, 2026).
Long-term follow-up is a reminder that advanced-therapy programs do not end when the initial intervention is complete. Safety and efficacy observation can require protocol maintenance long after early dosing, and material changes must remain inside the regulatory record.
ANVISA's current framework defines a protocol amendment as substantial when it may affect participant safety, physical or mental integrity, or the reliability and robustness of trial data. Those petitions are linked to the applicable DEEC and must include tracked changes, justification, and an assessment of the development impact (ANVISA RDC 945/2024, arts. 36–39).
Bottom Line: Early-stage sponsors should budget for the full regulatory lifecycle, not only initial authorization. Amendment strategy, safety reporting, annual follow-up, and closeout are part of trial design from the beginning.
Brazil's ReBEC registry lists a newly approved entry titled "Use of bone marrow stem cells (MesenCell) to treat patients who developed moderate or severe chronic graft-versus-host disease after a bone marrow transplant and did not respond to other treatments: a phase I clinical trial." The registry news page shows a registration and approval date of August 14, 2026 (ReBEC clinical-trial news).
The indication addresses a serious post-transplant complication in patients who have not responded to other treatments. The registry page confirms the Phase I designation and indication, but it does not expose the sponsor, city, site, enrollment target, intervention schedule, recruitment status, or CRO.
What to Focus On: The defensible signal is that a new Phase I record entered Brazil's public registry. It is not yet a basis for claims about trial scale, operational start, or sponsor activity. Those fields remain unknown until the underlying registry record or sponsor provides them.
Syneos Health has a Brazil talent-pipeline posting for CRA II or Senior CRA professionals, with São Paulo-only FSP and any-city Brazil FSO options. The home-based listing was updated on August 7, 2026 and includes a hiring bonus for new joiners (Syneos Health Brazil CRA listing).
The page expressly says it is for a possible upcoming opportunity rather than a confirmed live role. It therefore supports a capacity-planning signal, not a claim of a new office, client award, or active hiring campaign.
Why It Matters: Regulatory reform can increase throughput, but studies still depend on experienced monitors, investigators, coordinators, laboratories, and contracting teams. Sponsors evaluating Brazil should test resource availability against their protocol and proposed activation schedule instead of treating a national review clock as the full timeline.
Brazilian law gives clinical-research teams useful planning anchors. Ethics review should be completed within 30 working days after document completeness is accepted, while the ethics committee has up to 10 working days to accept or reject completeness. Sanitary analysis of primary clinical-trial petitions for registration purposes may take up to 90 working days (Brazil Law 14.874/2024, arts. 14 and 58).
RDC 945/2024 also allows ANVISA to request clarifications once, suspending the review clock, and requires the sponsor to answer within 30 working days. It covers substantial product modifications and protocol amendments under the same clinical-development framework (ANVISA RDC 945/2024, arts. 52–54).
These clocks are only part of the operating model. Trial imports, ethics sequencing, site contracts, investigator availability, training, data systems, and patient identification can determine whether an authorization becomes an activated site.
Bottom Line: Compare countries and sites using the complete path to first patient in, not one published review number.
In a Global Trial Accelerators™ conversation, Dr. Joseph Geraci, CSO/CTO and co-founder of NetraMark, discusses how AI may help researchers analyze small, noisy clinical datasets and identify explainable patient subpopulations that broad disease labels can obscure (Joseph Geraci on AI in Medicine).
The practical trial-design question is whether an average result masks a meaningful response in a defined subgroup. Geraci describes an approach that uses mathematically augmented models to identify candidate subpopulations and variables that can inform future inclusion criteria, stratification, and statistical analysis plans.
Why It Matters: AI does not replace prospective design or regulatory agreement. Its value is in generating testable, explainable hypotheses that can be carried into the next protocol.
For sponsors planning first-in-human, early-feasibility, or Phase I work, bioaccess® can map the regulatory, ethics, site, and operational dependencies into one evidence-based activation plan.
← All Global Trial Accelerators editions · Contact bioaccess®